Safety and procedural success of left atrial appendage exclusion with the lariat device: A systematic review of published reports and analytic review of the FDAMAUDE database

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1104-1109

  Chatterjee, Saurav ^a   Herrmann, Howard C ^b   Wilensky, Robert L ^b   Hirshfeld, John ^b   McCormick, Daniel ^b   Frankel, David S ^b   Yeh, Robert W ^c   Armstrong, Ehrin J ^d   Kumbhani, Dharam J ^e   Giri, Jay ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; DATA BASE; DEVICE SAFETY; HEART ATRIUM APPENDAGE; HEART ATRIUM APPENDAGE EXCLUSION; HEART SURGERY; HUMAN; PERICARDIAL DRAIN; PERICARDIAL EFFUSION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UROLOGICAL SNARE; ATRIAL FIBRILLATION; DEVICES; MINIMALLY INVASIVE SURGERY;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; HUMANS; MINIMALLY INVASIVE SURGICAL PROCEDURES;

EID: 84937437433     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1513     Document Type: Article

References (36)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: The Framingham Study. Arch Intern Med. 1987;147(9):1561-1564.
3. Hart RG, Pearce LA, AguilarMI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
4. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 1998;97(13):1231-1233.
5. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154(17):1945-1953.
6. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105-112.e15.
7. Wallace H, DaviesMW. The lack of antidotes for new oral anticoagulants. BMJ. 2014;348:g1438.
8. ManningWJ. Atrial fibrillation, transesophageal echo, electrical cardioversion, and anticoagulation. Clin Cardiol. 1995;18(2):58, 114.
9. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.
10. FDA Executive Summary: prepared for the December 11, 2013 Meeting of the Circulatory System: P130013: Devices Panel Boston Scientific WATCHMAN Left Atrial Appendage Closure Therapy. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM377356.pdf. Accessed May 26, 2014.
11. HornungM, Bertog SC, Franke J, et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J. 2013;34(43): 3362-3369.
12. Sievert H,Wunderlich N, Reiffenstein I, et al. Initial clinical experience with the Coherex FlatStent? and FlatStent? EF PFO closure system for in-tunnel PFO closure: results of the Coherex-EU study. Catheter Cardiovasc Interv. 2014;83(7):1135-1143.
13. Park D-W. Device Closure Versus Medical Therapy for Cryptogenic Stroke PatientsWith High-Risk Patent Foramen Ovale (DEFENSE-PFO). https://clinicaltrials.gov/ct2/show/NCT01550588 ?term=amplatzer&rank=14. Accessed May 26, 2014.
14. Wholey MH, Haller JD. An introduction to the Food and Drug Administration and how it evaluates new devices: establishing safety and efficacy. Cardiovasc Intervent Radiol. 1995;18(2):72-76.
15. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org. Accessed April 2, 2013.
16. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283 (15):2008-2012.
17. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical -epidemiology/oxford.htm. Accessed July, 2014.
18. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J AmColl Cardiol. 2013;62(2):108-118.
19. Gafoor S, Franke J, Bertog S, et al. Left atrial appendage occlusion in octogenarians: short-term and 1-year follow-up. Catheter Cardiovasc Interv. 2014;83(5):805-810.
20. Massumi A, Chelu MG, Nazeri A, et al. Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. Am J Cardiol. 2013;111(6):869-873.
21. PriceMJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the US transcatheter LAA ligation consortium. J AmColl Cardiol. 2014;64(6):565-572.
22. MillerMA, Gangireddy SR, Doshi SK, et al. Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device. Heart Rhythm. 2014;11(11):1853-1859.
23. Olmi S, Erba L,Magnone S, et al. Prospective study of laparoscopic treatment of incisional hernia by means of the use of composite mesh: indications, complications, mesh fixation materials and results [in Italian]. Chir Ital. 2005;57(6):709-716.
24. Devices, systems, and methods for closing the left atrial appendage: US 20080243183 A1. http://www.google.com/patents/US20080243183. Accessed May 24, 2014.
25. Devices, systems, and methods for closing the left atrial appendage:WO 2008121278A3. http://www.google.com/patents/WO2008121278A3?cl =en. Accessed May 26, 2014.
26. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887-1889.
27. Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg. 2010;10(2):306-311.
28. MontenegroMJ, Quintella EF, Damonte A, et al. Percutaneous occlusion of left atrial appendage with the Amplatzer Cardiac PlugTM in atrial fibrillation. Arq Bras Cardiol. 2012;98(2):143-150.
29. Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. Catheter Cardiovasc Interv. 2012;79(5):794-800.
30. Holmes DR Jr,Kar S, PriceMJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmColl Cardiol. 2014;64(1):1-12.
31. FDA Executive Summary: prepared for the October 8, 2014 Meeting of the Circulatory Systems Devices Panel: P130013: Boston Scientific WATCHMAN Left Atrial Appendage Closure Therapy. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM417199.pdf. Accessed November 4, 2014.
32. Kanderian AS, Gillinov AM, Pettersson GB, Blackstone E, Klein AL. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol. 2008;52(11): 924-929.
33. Center for Devices & Radiologic Health. Determination of intended use for 510(k) devices; guidance for CDRH staff (update to K98-1). December 3, 2002. http://www.fda.gov/downloads/MedicalDevices/.../ucm082166.pdf. Accessed August 12, 2014.
34. Ardaugh BM, Graves SE, Redberg RF. The 510(k) ancestry of ametal-on-metal hip implant. N Engl J Med. 2013;368(2):97-100.
35. Rome BN, Kramer DB, Kesselheim AS. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. JAMA. 2014;311(4):385-391.
36. Goodman SN, Redberg RF. Opening the FDA black box. JAMA. 2014;311(4):361-363.